Mechanisms of Action for Treatments in Multiple Sclerosis

No abstract is available for this paper.

• Publication year

  2012

• Venue

  BioDrugs

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.2165/00063030-200519050-00003PMID 16207071
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Axonal degeneration and progressive neurologic disability in multiple sclerosis

  2009cited by this paper
• Glatiramer acetate in the treatment of multiple sclerosis

  2007cited by this paper
• Progressive Multifocal Leukoencephalopathy After Natalizumab Therapy for Crohn's Disease

  2006cited by this paper
• Autoreactive CD8+ T cells in multiple sclerosis: a new target for therapy?

  2005cited by this paper
• Axon Reactive B Cells Clonally Expanded in the Cerebrospinal Fluid of Patients with Multiple Sclerosis

  2005cited by this paper
• Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease.

  2005cited by this paper
• Th1 and Th2 lymphocyte migration across the human BBB is specifically regulated by interferon beta and copolymer-1.

  2005cited by this paper
• Progressive multifocal leukoencephalopathy and natalizumab--unforeseen consequences.

  2005cited by this paper
• Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis.

  2005cited by this paper
• Progressive multifocal leukoencephalopathy in a patient treated with natalizumab.

  2005cited by this paper
• Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients

  2005cited by this paper
• Bystander modulation of chemokine receptor expression on peripheral blood T lymphocytes mediated by glatiramer therapy.

  2005cited by this paper
• Interferon-β-1a induces increases in vascular cell adhesion molecule: Implications for its mode of action in multiple sclerosis

  2005cited by this paper
• Inhibiting cytokines of the interleukin‐12 family: recent advances and novel challenges

  2004cited by this paper
• Regulation of differentiation and functional properties of monocytes and monocyte-derived dendritic cells by interferon beta in multiple sclerosis

  2004cited by this paper
• Effects of interferon-beta on microglial functions as inflammatory and antigen presenting cells in the central nervous system.

  2004cited by this paper
• Abnormal levels of interferon-gamma receptors in active multiple sclerosis are normalized by IFN-beta therapy: implications for control of apoptosis.

  2004cited by this paper
• IFN-β1a and IFN-β1b have different patterns of influence on cytokines

  2004cited by this paper
• Effects of interferon-β on microglial functions as inflammatory and antigen presenting cells in the central nervous system

  2004cited by this paper
• Biologic role of interferon beta in multiple sclerosis

  2004cited by this paper
• Interferon-β1b leads to a short-term increase of soluble but long-term stabilisation of cell surface bound adhesion molecules in multiple sclerosis

  2004cited by this paper
• Beta-Interferon Treatment Reduces Human Herpesvirus-6 Viral Load in Multiple Sclerosis Relapses but Not in Remission

  2004cited by this paper
• IFN-beta1a and IFN-beta1b have different patterns of influence on cytokines.

  2004cited by this paper
• VLA-4 integrin concentrates at the peripheral supramolecular activation complex of the immune synapse and drives T helper 1 responses.

  2004cited by this paper
• The Interleukin (IL)‐2 Family Cytokines: Survival and Proliferation Signaling Pathways in T Lymphocytes

  2004cited by this paper
• Cytokines and adhesion molecules in multiple sclerosis patients treated with interferon-beta1b.

  2004cited by this paper
• Decreased integrin gene expression in patients with MS responding to interferon-beta treatment.

  2004cited by this paper
• Interferon‐β stabilizes barrier characteristics of brain endothelial cells in vitro

  2004cited by this paper
• Neuroprotection and glatiramer acetate: the possible role in the treatment of multiple sclerosis.

  2004cited by this paper
• Interferon-β enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis

  2004cited by this paper
• A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis.

  2004cited by this paper
• New immunosuppressants with potential implication in multiple sclerosis.

  2004cited by this paper
• What do we know about the mechanism of action of disease-modifying treatments in MS?

  2004influential reference
• Mechanism of action of mitoxantrone

  2004influential reference
• Brain-derived neurotrophic factor.

  2004cited by this paper
• Increased CXCL8 (IL-8) expression in Multiple Sclerosis.

  2004cited by this paper
• Interferon-beta stabilizes barrier characteristics of brain endothelial cells in vitro.

  2004cited by this paper
• Rationale for the use of mitoxantrone in multiple sclerosis.

  2004cited by this paper
• Genomic effects of IFN-beta in multiple sclerosis patients.

  2003cited by this paper
• Novel IL-12 family members shed light on the orchestration of Th1 responses

  2003cited by this paper
• Genomic Effects of IFN-β in Multiple Sclerosis Patients 1

  2003cited by this paper
• Alpha4 integrins as therapeutic targets in autoimmune disease.

  2003cited by this paper
• Temporal variations of adhesion molecules and matrix metalloproteinases in the course of MS.

  2003cited by this paper
• Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain

  2003cited by this paper
• Regulation by interferon beta-1a of reactive oxygen metabolites production by lymphocytes and monocytes and serum sulfhydryls in relapsing multiple sclerosis patients.

  2003cited by this paper
• Immunomodulation in multiple sclerosis: from immunosuppression to neuroprotection.

  2003influential reference
• Regulation by interferon β-1a of reactive oxygen metabolites production by lymphocytes and monocytes and serum sulfhydryls in relapsing multiple sclerosis patients

  2003cited by this paper
• Timing of IFN-β Exposure during Human Dendritic Cell Maturation and Naive Th Cell Stimulation Has Contrasting Effects on Th1 Subset Generation: A Role for IFN-β-Mediated Regulation of IL-12 Family Cytokines and IL-18 in Naive Th Cell Differentiation1

  2003cited by this paper
• A controlled trial of natalizumab for relapsing multiple sclerosis.

  2003influential reference
• The 'immunological-synapse' at its APC side in relapsing and secondary-progressive multiple sclerosis: modulation by interferon-beta.

  2003cited by this paper
• Effects of Mitoxantrone on Multiple Sclerosis Patients’ Lymphocyte Subpopulations and Production of Immunoglobulin, TNF-alpha and IL-10

  2003cited by this paper
• Efficient central nervous system remyelination requires T cells

  2003cited by this paper
• Interferon-β differentially regulates expression of the IL-12 family members p35, p40, p19 and EBI3 in activated human dendritic cells

  2002cited by this paper
• Interferon-beta differentially regulates expression of the IL-12 family members p35, p40, p19 and EBI3 in activated human dendritic cells.

  2002cited by this paper
• Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial.

  2002cited by this paper
• Modulation of astrocyte inducible nitric oxide synthase and cytokine expression by interferon β is associated with induction and inhibition of interferon γ‐activated sequence binding activity

  2002cited by this paper
• Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor.

  2002cited by this paper
• Anti-viral properties of interferon beta treatment in patients with multiple sclerosis

  2002cited by this paper
• Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS

  2002cited by this paper
• Differential mechanisms of action of interferon-beta and glatiramer aetate in MS.

  2002cited by this paper
• Integrins: bidirectional, allosteric signaling machines.

  2002cited by this paper
• Differential mechanisms of action of interferon-β and glatiramer acetate in MS

  2002cited by this paper
• Glatiramer acetate and IFN-β act on dendritic cells in multiple sclerosis

  2001cited by this paper
• Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

  2001cited by this paper
• Factors modifying the migration of lymphocytes across the blood-brain barrier.

  2001cited by this paper
• IFN-β1a Modulates the Expression of CTLA-4 and CD28 Splice Variants in Human Mononuclear Cells: Induction of Soluble Isoforms

  2001cited by this paper
• Anoikis and metastatic potential of cloudman S91 melanoma cells.

  2001cited by this paper
• Glatiramer acetate in the treatment of multiple sclerosis

  2001cited by this paper
• Glatiramer acetate and IFN-beta act on dendritic cells in multiple sclerosis.

  2001cited by this paper
• PRISMS-4: Long-term efficacy of interferon-&bgr;-1a in relapsing MS

  2001cited by this paper
• Interferon-beta therapy downregulates the anti-apoptosis protein FLIP in T cells from patients with multiple sclerosis.

  2001cited by this paper
• European/Canadian multicenter, double‐blind, randomized, placebo‐controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosis

  2001cited by this paper
• T lymphocytes conditioned with Interferon beta induce membrane and soluble VCAM on human brain endothelial cells.

  2001cited by this paper
• Mechanisms of action of glatiramer acetate in multiple sclerosis

  2001cited by this paper
• Immunomodulatory effects of interferon beta-1a in multiple sclerosis.

  2001cited by this paper
• Regulation of chemokine receptor CCR5 and production of RANTES and MIP-1alpha by interferon-beta.

  2001cited by this paper
• Interferon-β therapy downregulates the anti-apoptosis protein FLIP in T cells from patients with multiple sclerosis

  2001cited by this paper
• Matrix metalloproteinases and their tissue inhibitors as markers of disease subtype and response to interferon‐β therapy in relapsing and secondary‐progressive multiple sclerosis patients

  2001cited by this paper
• PRISMS-4: Long-term efficacy of interferon-β-1a in relapsing MS

  2001cited by this paper
• RANTES production and expression is reduced in relapsing-remitting multiple sclerosis patients treated with interferon-beta-1b.

  2000cited by this paper
• Glatiramer acetate (copolymer-1)-specific, human T cell lines: cytokine profile and suppression of T cell lines reactive against myelin basic protein.

  2000cited by this paper
• Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis.

  2000cited by this paper
• Mechanisms of immunomodulation by glatiramer acetate

  2000cited by this paper
• Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination

  2000cited by this paper
• Cladribine and progressive MS

  2000cited by this paper
• Multiple sclerosis: comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells.

  2000cited by this paper
• Multiple sclerosis: Pro- and anti-inflammatory cytokines and metalloproteinases are affected differentially by treatment with IFN-β

  2000cited by this paper
• VLA-4/CD49d downregulated on primed T lymphocytes during interferon-beta therapy in multiple sclerosis.

  2000cited by this paper
• Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H

  1999cited by this paper
• Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis.

  1999cited by this paper
• Changes of serum sICAM-1 and MMP-9 induced by rIFNbeta-1b treatment in relapsing-remitting MS.

  1999cited by this paper
• The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group.

  1999cited by this paper
• The effect of anti-α4 integrin antibody on brain lesion activity in MS

  1999cited by this paper
• Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation.

  1998cited by this paper
• Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

  1998cited by this paper
• Influence of IFN‐β1b (Betaferon) on cytokine mRNA profiles in blood mononuclear cells and plasma levels of soluble VCAM‐1 in multiple sclerosis

  1998cited by this paper
• Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.

  1998cited by this paper
• Interferon beta-1b inhibits reactive oxygen species production in peripheral blood monocytes of patients with relapsing-remitting multiple sclerosis.

  1998cited by this paper
• Interferon beta in the treatment of multiple sclerosis

  1998cited by this paper
• Interferon‐β Is a Potent Promoter of Nerve Growth Factor Production by Astrocytes

  1997cited by this paper

• Vortioxetine Ameliorates Experimental Autoimmune Encephalomyelitis Model of Multiple Sclerosis in Mice via Activation of PI3K/Akt/CREB/BDNF cascade and Modulation of Serotonergic Pathway Signaling.

  2024cites this paper
• Alopecia in Multiple Sclerosis Patients Treated with Disease Modifying Therapies

  2022cites this paper
• State of art and limitations in genetic engineering to induce stable chondrogenic phenotype.

  2018cites this paper
• Biosimilars as Therapeutic Agents against Neurodegenerative Diseases-A Focus on Multiple Sclerosis

  2018cites this paper
• Therapeutic Advances in Neurological Disorders

  2016cites this paper
• Interferon β in Multiple Sclerosis

  2016cites this paper
• Interferon beta-1 a for the maintenance of remission in patients with Crohn ' s disease : results of a phase II dose-finding study

  2015influential citation
• Myelin basic protein immunosensor for multiple sclerosis detection based upon label-free electrochemical impedance spectroscopy.

  2013cites this paper
• Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing–remitting multiple sclerosis: subgroup analyses of the DEFINE study

  2013cites this paper
• Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing–remitting multiple sclerosis: subgroup analyses of the CONFIRM study

  2013cites this paper
• Lipoic Acid, Inflammation and Diseases of the Nervous System 102

  2012cites this paper
• First-Line Disease-Modifying Therapies in Paediatric Multiple Sclerosis

  2012cites this paper
• Subcutaneous Recombinant Interferon-β-1a (Rebif®)

  2011cites this paper
• Cladribine: Mode of Action and Implications for Treatment of Multiple Sclerosis

  2011cites this paper
• Development of oral cladribine for the treatment of multiple sclerosis

  2010cites this paper
• The Potential Role of B Cell-Targeted Therapies in Multiple Sclerosis

  2010cites this paper
• Atacicept: targeting B cells in multiple sclerosis

  2010cites this paper
• Neutralizing antibodies and the biological response to interferon-beta therapy

  2010cites this paper
• Eficacia del concepto bobath en el tratamiento de fisioterapia de la esclerosis múltiple recurrente-remitente

  2010cites this paper
• Drug Therapies for the Treatment of Multiple Sclerosis

  2009cites this paper
• [Pathogenetic treatment of multiple sclerosis: the present and the future].

  2009cites this paper
• Treatment of multiple sclerosis.

  2009cites this paper
• Interferon beta-1a for the maintenance of remission in patients with Crohn's disease: results of a phase II dose-finding study

  2009cites this paper
• Neutralizing antibodies explain the poor clinical response to Interferon beta in a small proportion of patients with Multiple Sclerosis: a retrospective study

  2009cites this paper
• [Atacicept: a new B lymphocyte-targeted therapy for multiple sclerosis].

  2009cites this paper
• High‐Dose Cyclophosphamide in the Treatment of Multiple Sclerosis

  2009cites this paper
• The effect of interferon-beta on mouse neural progenitor cell survival and differentiation.

  2009cites this paper
• B-cell-targeted treatment for multiple sclerosis: mechanism of action and clinical data

  2008cites this paper
• The role of B cells in multiple sclerosis: rationale for B-cell-targeted therapies

  2008cites this paper
• Expression of the inhibitor of apoptosis protein family in multiple sclerosis reveals a potential immunomodulatory role during autoimmune mediated demyelination

  2008cites this paper
• Interferon-β stabilizes barrier characteristics of the blood–brain barrier in four different species in vitro

  2008cites this paper
• The Rebif® New Formulation Story

  2007cites this paper
• Interferon-beta

  2007cites this paper
• Management of worsening multiple sclerosis with mitoxantrone: a review.

  2006cites this paper
• Disease-modifying drugs for multiple sclerosis: current and future aspects

  2006cites this paper